UnknownNot Applicable

Molecular Epidemiology of Hepatitis B in Cayenne General Hospital, French Guiana

French Guiana400 participantsStarted 2021-02-11

Plain-language summary

In South America, the prevalence of HBV is variable but high (\> 8%) in the Amazon basin. In some areas, a third of HBsAg carriers are also infected with HDV, a major comorbidity factor. The pre-core mutations are associated with the negative HBe Ag phenotype which is associated with a more severe course. These mutations are of increasing and high frequency. French Guiana is populated by populations of African, European and Asian origins with chains of viral transmission which are not known and viruses probably of different origins with variable virulence and transmission potentials.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 18 years old * Person with confirmed chronic hepatitis B * Person who does not object to their participation in the protocol * HBV viral load\> = 500 copies / mL * Person who has planned / is willing to have their next HBV assessment of current care taken at the Cayenne Hospital center Exclusion Criteria: * Refusal to participate * Age \<18 years old * Person opposing their participation in the protocol * HBV viral load \<500 copies / mL * Person who has not planned / been unwilling to have their next HBV assessment of current care taken at the Cayenne Hospital center

What they're measuring

Hepatitis B virus (HBV) sequencing

Timeframe: 2 years

Trial details

NCT IDNCT04886102

SponsorCentre Hospitalier de Cayenne

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-02-01

Contact for this trial

Roxane SCHAUB, MD

+594 594 39 55 96 roxane.schaub@ch-cayenne.fr

View on ClinicalTrials.gov More Hepatitis B, Chronic trials